Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/17931
Title: Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study
Authors: CLAES, Nele 
DHAEZE, Tessa 
FRAUSSEN, Judith 
BROUX, Bieke 
VAN WIJMEERSCH, Bart 
STINISSEN, Piet 
HELLINGS, Niels 
SOMERS, Veerle 
Hupperts, Raymond
Issue Date: 2014
Source: PloS one, 9 (10), p. 1-8
Abstract: Background and objective: The long term effects of fingolimod, an oral treatment for relapsing-remitting (RR) multiple sclerosis (MS), on blood circulating B and T cell subtypes in MS patients are not completely understood. This study describes for the first time the longitudinal effects of fingolimod treatment on B and T cell subtypes. Furthermore, expression of surface molecules involved in antigen presentation and costimulation during fingolimod treatment are assessed in MS patients in a 12 month follow-up study. Methods: Using flow cytometry, B and T cell subtypes, and their expression of antigen presentation, costimulation and migration markers were measured during a 12 month follow-up in the peripheral blood of MS patients. Data of fingolimodtreated MS patients (n = 49) were compared to those from treatment-naive (n = 47) and interferon-treated (n = 27) MS patients. Results: In the B cell population, we observed a decrease in the proportion of non class-switched and class-switched memory B cells (p,0.001), both implicated in MS pathogenesis, while the proportion of naive B cells was increased during fingolimod treatment in the peripheral blood (PB) of MS patients (p,0.05). The remaining T cell population, in contrast, showed elevated proportions of memory conventional and regulatory T cells (p,0.01) and declined proportions of naive conventional and regulatory cells (p,0.05). These naive T cell subtypes are main drivers of MS pathogenesis. B cell expression of CD80 and CD86 and programmed death (PD) -1 expression on circulating follicular helper T cells was increased during fingolimod follow-up (p,0.05) pointing to a potentially compensatory mechanism of the remaining circulating lymphocyte subtypes that could provide additional help during normal immune responses. Conclusions: MS patients treated with fingolimod showed a change in PB lymphocyte subtype proportions and expression of functional molecules on T and B cells, suggesting an association with the therapeutic efficacy of fingolimod.
Notes: Somers, V (reprint author),Hasselt Univ, Biomed Res Inst, Diepenbeek, Belgium veerle.somers@uhasselt.be
Document URI: http://hdl.handle.net/1942/17931
ISSN: 1932-6203
e-ISSN: 1932-6203
DOI: 10.1371/journal.pone.0111115
ISI #: 000343943700063
Rights: © 2014 Claes et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Category: A1
Type: Journal Contribution
Validations: ecoom 2015
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
journal.pone.0111115.pdfPublished version771.96 kBAdobe PDFView/Open
Show full item record

SCOPUSTM   
Citations

54
checked on Sep 5, 2020

WEB OF SCIENCETM
Citations

77
checked on Mar 29, 2024

Page view(s)

76
checked on Aug 31, 2022

Download(s)

102
checked on Aug 31, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.